These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6453 related articles for article (PubMed ID: 24756797)

  • 1. Trametinib.
    Zeiser R
    Recent Results Cancer Res; 2014; 201():241-8. PubMed ID: 24756797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trametinib (GSK1120212) in the treatment of melanoma.
    Salama AK; Kim KB
    Expert Opin Pharmacother; 2013 Apr; 14(5):619-27. PubMed ID: 23432625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
    Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
    Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.
    King JW; Nathan PD
    Future Oncol; 2014; 10(9):1559-70. PubMed ID: 25145427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trametinib: a novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma.
    Chung C; Reilly S
    Am J Health Syst Pharm; 2015 Jan; 72(2):101-10. PubMed ID: 25550132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trametinib in metastatic melanoma.
    Chopra N; Nathan PD
    Expert Rev Anticancer Ther; 2015; 15(7):749-60. PubMed ID: 26107021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib in the treatment of melanoma.
    Thota R; Johnson DB; Sosman JA
    Expert Opin Biol Ther; 2015 May; 15(5):735-47. PubMed ID: 25812921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():20-31. PubMed ID: 27956260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
    Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
    Dai C; Shen L; Jin W; Lv B; Liu P; Wang X; Yin Y; Fu Y; Liang L; Ma Z; Zhang X; Wang Y; Xu D; Chen Z
    Toxicol Appl Pharmacol; 2020 Dec; 408():115273. PubMed ID: 33035574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.
    Estrada-Bernal A; Chatterjee M; Haque SJ; Yang L; Morgan MA; Kotian S; Morrell D; Chakravarti A; Williams TM
    Cell Cycle; 2015; 14(23):3713-24. PubMed ID: 26505547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock.
    Shi-Lin D; Yuan X; Zhan S; Luo-Jia T; Chao-Yang T
    Biochem Biophys Res Commun; 2015 Mar; 458(3):667-673. PubMed ID: 25684183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trametinib: first global approval.
    Wright CJ; McCormack PL
    Drugs; 2013 Jul; 73(11):1245-54. PubMed ID: 23846731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.
    Lian T; Li C; Wang H
    Cancer Treat Rev; 2019 Dec; 81():101907. PubMed ID: 31715422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of MEK inhibitors in the treatment of metastatic melanoma.
    Grimaldi AM; Simeone E; Ascierto PA
    Curr Opin Oncol; 2014 Mar; 26(2):196-203. PubMed ID: 24419498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for MEK inhibitors for treating cancer.
    Martin-Liberal J; Lagares-Tena L; Larkin J
    Expert Opin Drug Saf; 2014 Apr; 13(4):483-95. PubMed ID: 24597490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 323.